Seqera Labs, recognized for its secure workflow orchestration software in the life sciences domain, is aligning forces with Genomics England, a government-owned entity, which initiated the notable 100,000 Genomes Project in alliance with the NHS. This collaboration aims to enhance the scope and proficiency of whole genome analysis, paving the way for a broader patient base to avail genomic healthcare benefits.

Valo Therapeutics Oy (ValoTx), a frontrunner in the development of advanced immunotherapies for cancer, has initiated its Phase I trial of PeptiCRAd-1, a pioneer in the realm of immuno-oncology. The first participant, enrolled in this Germany-based trial, has received the treatment without any immediate safety issues, according to the company's recent press release.

PharmEnable, an innovative drug discovery firm, recently secured $7.5M in Pre-Series A financing, reflecting growing confidence in its proprietary AI-based drug discovery platform and potential contributions to the treatment of cancer and neurological diseases. This move signifies the latest milestone in the integration of AI technology into drug discovery, a trend that's been steadily reshaping the biopharma landscape.

The landscape of biotechnology is rapidly evolving, with coding and machine learning becoming integral to the innovative processes. A recent industry survey by Cradle, a platform that empowers scientists to design and program proteins, and Bits in Bio, a global community dedicated to creating software for science, reveals a detailed picture of current trends within the synthetic biology sector.

PsychoGenics, a prominent player in AI-enabled phenotypic drug discovery and preclinical CRO services, has recently unveiled eCube, an innovative pharmaco-electroencephalography (pharmacoEEG) platform designed to enhance phenotypic drug discovery. By employing machine learning algorithms, eCube has the potential to identify compounds that can penetrate the central nervous system (CNS) and predict their therapeutic applications for neuropsychiatric disorders. The platform achieves this by comparing EEG profiles of novel compounds to an extensive pharmacoEEG database containing hundreds of doses of CNS-active reference drugs.

The brain-computer interface (BCI) technology domain is constantly progressing as researchers and companies collaborate to devise inventive solutions that connect the human brain with external devices. This expanding sector, driven by the need for better communication, rehabilitation, and augmented cognitive capabilities, has given rise to both invasive and non-invasive BCI techniques. In this article, we will delve into the current status of brain-computer interface technology, explore the distinctions between invasive and non-invasive BCIs, and consider the potential consequences for the future development of this rapidly changing field.

Proscia, a company specializing in digital and computational pathology solutions, recently announced updates to its preclinical research and development (R&D) offerings. These improvements target the company's flagship software platform, Concentriq® for Research, a tool many pharmaceutical companies use to manage pathology workflows and data. The expansion aims to streamline Good Laboratory Practice (GLP) and non-regulated drug safety studies, potentially influencing the industry.

(Last updated: October 05, 2022)

The interest of pharma organizations in DNA-encoded chemical libraries (DEL) technology has been growing over the years, with numerous pharma organizations now having their internal screening programs using DELs or outsourcing capabilities from specialized DEL providers.

This report provides a bird's view of the DEL market, including a summary of DEL technology benefits and limitations, key players, major research deals, and several examples of successful hit discovery programs using DELs. 

It took more than eight decades since the landmark experiments on calorie restrictions in 1930th to get to a point when the first wave of new anti-aging drugs began human testing. This first generation of longevity therapeutics, including senolytics, rapamycin, mitochondrial gene therapy, and WNT pathway regulators among others, are not directly targeting aging (yet), rather they aim to treat specific ailments by slowing or reversing a fundamental process of aging. However, the rate of progress in this area allows for some constructive optimism towards being able to actually expand the healthy lifespan in the foreseeable future.

The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about 11% for drug candidates moving from Phase 1 towards approval. Even if the drug candidate is safe and efficacious, clinical trials might fail due to the lack of financing, insufficient enrollment, or poor study design. [Fogel DB. 2018].  

Artificial Intelligence (AI) is increasingly perceived as a source of opportunities to improve the operational efficiency of clinical trials and minimize clinical development costs.  Typically AI vendors offer their services and expertise in the three main areas. AI start-ups in the first area help to unlock information from disparate data sources, such as scientific papers, medical records, disease registries, and even medical claims by applying Natural Language Processing (NLP). This can support patient recruitment and stratification, site selection, and improve clinical study design and understanding of disease mechanisms. As an example, about 18 % of clinical studies fail due to insufficient recruitment, as a 2015 study reported.